Host: John J. Russell, MD <br>

Guest: Wendy S. Lane, MD <br>

In this interview, Dr. Lane will review the clinical evidence supporting combinations of GLP-1 receptor agonists with basal insulin for the treatment of type 2 diabetes.

Host: John J. Russell, MD Guest: Wendy S. Lane, MD In this interview, Dr. Lane will review the clinical evidence supporting combinations of GLP-1 receptor agonists with basal insulin for the treatment of type 2 diabetes.

What is the Rationale for Fixed-Ratio Combinations of Basal Insulin Analogs and GLP-1 Receptor Agonists?

As the number of Americans living with diabetes continues to rise, staying up to date on the latest diabetes research is more essential than ever to help patients achieve glucose control. With Diabetes Discourse, you’ll hear from diabetes and endocrinology experts on emerging research, diagnostic and treatment strategies, and various elements that impact a patient’s disease course, including risk factors, vitamin and mineral supplementation, physical activity, and kidney disease.
Because when it comes to diabetes, glucose control is just the beginning.

Medicine

As the number of Americans living with diabetes continues to rise, staying up to date on the latest diabetes research is more essential than ever to help patients achieve glucose control. With Diabetes Discourse, you’ll hear from diabetes and endocrinology experts on emerging research, diagnostic and treatment strategies, and various elements that impact a patient’s disease course, including risk factors, vitamin and mineral supplementation, physical activity, and kidney disease. Because when it comes to diabetes, glucose control is just the beginning.

Share What is the Rationale for Fixed-Ratio Combinations of Basal Insulin Analogs and GLP-1 Receptor Agonists?

Sign up to save your podcasts

What is the Rationale for Fixed-Ratio Combinations of Basal Insulin Analogs and GLP-1 Receptor Agonists?

What is the Rationale for Fixed-Ratio Combinations of Basal Insulin Analogs and GLP-1 Receptor Agonists?